Clinical trials: CART Cells
Hematologic Disorders and Bone Marrow Failure, Hematopoietic Stem Cell Transplantation (HSCT) or Cellular Therapy (CART)
Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients
For many patients with hematologic disorders and bone marrow failure, hematopoietic stem cell transplantation (HSCT) or cellular therapy (CART) offers a curative treatment option.
- Trial name
- NCT04723706
- Testing
- COVID-19 serology IgG
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Henry Ford Health System
Acute Myeloid Leukemia
Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)
This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of anti-CLL1 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CLL1 positive relapsed or refractory acute…
- Trial name
- NCT04884984
- Testing
- anti-CLL1 CART
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma
BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma
This is a single arm, open label, multi-center prospective study to explory the safety and efficacy of GC012F CAR-T cells in patient diagnosed with high-risk chromosomal abnormalities BCMA+ multiple myeloma(MM).
- Trial name
- NCT04617704
- Testing
- GC012F injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Changzheng Hospital
Leukemia, Lymphoma
Cardiovascular Effects of CART Cell Therapy
This is an observational study aiming to prospectively define the rate of occurrence, natural history and progression of cardiac dysfunction in adults, and to identify the patients at high risk of developing cardiovascular…
- Conditions
- Leukemia, Lymphoma, Cardiotoxicity, Risk Factor, Cardiovascular
- Trial name
- CVE-CART (NCT04026737)
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Multiple Myeloma
CART-BCMA Cells for Multiple Myeloma
Open-label, single-center, pilot study to assess the safety and feasibility of infusion of autologous T cells expressing BCMA (B-cell maturation antigen)-specific chimeric antigen receptors with tandem TCR and 4-1BB costimulatory…
- Trial name
- NCT02546167
- Testing
- CART-BCMA
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pennsylvania
Multiple Myeloma
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
- Trial name
- NCT03994705
- Testing
- Descartes-11, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Cartesian Therapeutics
Adult T-Cell Lymphoma/Leukaemia, Anaplastic Large Cell Lymphoma
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies
The overall purpose of this study is to explore the safety and therapeutic effect of CD30-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Refractory/Relapsed lymphocyte malignancies.
- Conditions
- Adult T-Cell Lymphoma/Leukaemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, NK/T-cell Lymphoma
- Trial name
- NCT04008394
- Testing
- Anti-CD30 CAR T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Acute Myeloid Leukemia (AML)
CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
This study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult subjects with relapsed or refractory AML.
- Trial name
- CART123 (NCT07464951)
- Testing
- Anti-CD123 LV redirected T cells (CART123), Ruxolitinib (JAKAVI®)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stephan Grupp MD PhD
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I trial studies the side effects and how well CART-BCMA/CS1 works in treating patients with multiple myeloma (MM) that has come back (relapsed) or that does not respond to treatment (refractory).
- Trial name
- NCT05950113
- Testing
- Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Acute Myeloid Leukemia
CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia
This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of targeted CD38 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD38 positive relapsed or refractory…
- Trial name
- NCT04351022
- Testing
- CART-38
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
This is a Phase 1/2, open-label, single arm, multicohort study to evaluate the safety and efficacy of JCAR017 in pediatric subjects aged ≤ 25 years with CD19+ r/r B-ALL and B-NHL.
- Trial name
- NCT03743246
- Testing
- JCAR017, Lymphodepleting, Fludarabine
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 21 people
- Sponsor
- Celgene
Relapsed and Refractory CD5 Hematological Tumors
CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors
This is an investigator-initiated dose-finding clinical study with the primary objective of evaluating the safety of CD5CART in the treatment of subjects with relapsed and refractory CD5 hematological malignancies and to explore…
- Trial name
- NCT07234110
- Testing
- Fully human CD5 chimeric antigen receptor T cell injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, CART Therapy
Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)
CAR-T cell or bispecific antibody therapies are a new treatment option for adult patients with aggressive forms of lymphoma or so-called plasma cell diseases ('multiple myeloma', 'plasma cell myeloma') that could not be cured…
- Conditions
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, CART Therapy, Bispecific Antibody, Geriatric Hematology
- Trial name
- GA-ACT (NCT07309497)
- Testing
- pragmatic geriatric assessment
- Where
- 2 sites in Switzerland
- Volunteers
- 208 people
- Sponsor
- University of Zurich
Hiv
Study of the Effects of Farnesoid X Receptor (FXR) Ligands on the Reactivation of Latent Provirus
The Farnesoid X receptor (FXR) is a nuclear receptor that controls the transcription of many genes involved in lipid and glucose metabolism.
- Trial name
- FXReservoir (NCT03618862)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 38 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
CART-PSMA Cells for Advanced Prostate Cancer
This is a single center, open-label phase 1 study to assess the safety and feasibility of PSMA-specific CAR modified autologous T cells (CART-PSMA cells) in patients with advanced prostate cancer.
- Trial name
- NCT05656573
- Testing
- CART-PSMA cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nova Therapeutics LLC
Pancreatic Cancer
Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
This is a study in which pancreatic cancer patients receive a combination therapy with CART-meso cells and CART19 cells administered at 3 days after one dose of cyclophosphamide.
- Trial name
- NCT02465983
- Testing
- CART-meso-19 T cells, Cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Pennsylvania
Advanced EGFR-positive Solid Tumors
Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous T cells may make the body build immune response to kill cancer cells.
- Trial name
- CART-EGFR (NCT01869166)
- Testing
- CART-EGFR
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Melanoma
Combination Immunotherapy Targeting Melanoma
The purpose of this study is to assess the feasibility, safety and efficacy of combination immunotherapy based on CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines modified with GM-CSF and B7-2 (CD86)…
- Trial name
- NCT06739226
- Testing
- Antigen-specific CAR T, CTL and DCvac to treat melanoma.
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma
This is a single center, prospective cohort study to to evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation(ASCT) bridging chimeric antigen receptor T (CART) cell therapy in the treatment of…
- Trial name
- NCT04923789
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Soochow University
B Cell Lymphoma
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor 19 (CD19 CART) cells in relapsed and refractory patients with CD19+ B cell lymphoma.
- Trial name
- NCT03146533
- Testing
- Fludarabine, Cyclophosphamide, CD19 CART
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Second People's Hospital